Abstract：
Cancer immunotherapy has revolutionized the treatment landscape by harnessing the power of the immune system to combat malignancies. Two of the most promising players in this field are cluster of differentiation 24 (CD24) and sialic acid-binding Ig-like lectin 10 (Siglec-10), and both of them play pivotal roles in modulating immune responses. CD24, a cell surface glycoprotein, emerges as a convincing fundamental signal transducer for therapeutic intervention, given its significant implication in the processes related to tumour progression and immunogenic evasion. Additionally, the immunomodulatory functions of Siglec-10, a prominent member within the Siglec family of immune receptors, have recently become a crucial point of interest, particularly in the context of the tumour microenvironment. Hence, the intricate interplay of both CD24 and Siglec-10 assumes a critical role in fostering tumour growth, facilitating metastasis and also orchestrating immune evasion. Recent studies have found multiple evidences supporting the therapeutic potential of targeting CD24 in cancer treatment. Siglec-10, on the other hand, exhibits immunosuppressive properties that contribute to immune tolerance within the tumour microenvironment. Therefore, we delve into the complex mechanisms through which Siglec-10 modulates immune responses and facilitates immune escape in cancer. Siglec-10 also acts as a viable target for cancer immunotherapy and presents novel avenues for the development of therapeutic interventions. Furthermore, we examine the synergy between CD24 and Siglec-10 in shaping the immunosuppressive tumour microenvironment and discuss the implications for combination therapies. Therefore, understanding the roles of CD24 and Siglec-10 in cancer immunotherapy opens exciting possibilities for the development of novel therapeutics.
摘要：
癌症免疫疗法通过利用免疫系统的力量来对抗恶性肿瘤，彻底改变了治疗领域。该领域最有前途的两个参与者是分化簇24（CD24）和唾液酸结合Ig样凝集素10（Siglec-10），两者都在调节免疫反应中起着关键作用。CD24，一种细胞表面糖蛋白，作为治疗干预的令人信服的基本信号转换器，鉴于其在与肿瘤进展和免疫原性逃避相关的过程中的重要意义。此外,Siglec-10是免疫受体Siglec家族中的一个重要成员，最近已经成为一个关键的兴趣点，特别是在肿瘤微环境的背景下。因此，CD24和Siglec-10的复杂相互作用在促进肿瘤生长中发挥关键作用，促进转移和协调免疫逃避。最近的研究发现了多种证据支持在癌症治疗中靶向CD24的治疗潜力。另一方面，Siglec-10，表现出免疫抑制特性，有助于肿瘤微环境内的免疫耐受。因此,我们深入研究了Siglec-10调节免疫应答和促进癌症免疫逃逸的复杂机制.Siglec-10还可以作为癌症免疫疗法的可行靶标，并为开发治疗性干预措施提供了新的途径。此外，我们研究了CD24和Siglec-10在塑造免疫抑制肿瘤微环境方面的协同作用,并讨论了联合治疗的意义.因此,了解CD24和Siglec-10在癌症免疫治疗中的作用为开发新的治疗方法开辟了令人兴奋的可能性.
